Search research articles
Contact Us
Filters
Showing results (111-120 of 262) with videos related to
Page
of 27
Sort By:
Clinical and Experimental Medicine
|
September 11, 2024
Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance
Si Lu, Rongjie Zhao, Yicheng Han, et al.
Frontiers in Pharmacology
|
August 20, 2024
Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
Xuanhong Jin, Yang Pan, Cheng Cheng, et al.
Bioactive Materials
|
June 29, 2022
Macrophage membrane-biomimetic adhesive polycaprolactone nanocamptothecin for improving cancer-targeting efficiency and impairing metastasis
Kangkang Ying, Yifeng Zhu, Jianqin Wan, et al.
Plos One
|
June 14, 2013
AIB1 cooperates with ERα to promote epithelial mesenchymal transition in breast cancer through SNAI1 activation
Miao Wang, Feng Zhao, Shujing Li, et al.
Cellular and Molecular Life Sciences : CMLS
|
December 10, 2022
B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis
Xiaoling Zhang, Hao Liu, Haidong Wang, et al.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
|
July 20, 2016
[Establishment of "in-hospital critical illness management system" in general hospital: establishment of "general critical medicine" mode]
Tao Zhu, Daoyang Zhou, Konghan Pan, et al.
Theranostics
|
June 20, 2020
An ultralow dose of the NADPH oxidase inhibitor diphenyleneiodonium (DPI) is an economical and effective therapeutic agent for the treatment of colitis-associated colorectal cancer
Yue Kuai, Hao Liu, Dongyu Liu, et al.
Frontiers in Pharmacology
|
March 21, 2022
Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
Li Chen, Hao Sun, Ruihu Zhao, et al.
Cancer Letters
|
June 7, 2016
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3
Jiawei Shou, Liangkun You, Junlin Yao, et al.
Journal of Cancer
|
August 21, 2018
Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China
Chongya Zhai, Yulan Cai, Fang Lou, et al.
Page
of 27
Search research articles
Search
Showing results (111-120 of 262) with videos related to
Sort By:
Page
of 27
Clinical and Experimental Medicine
|
September 11, 2024
Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance
Si Lu, Rongjie Zhao, Yicheng Han, et al.
Frontiers in Pharmacology
|
August 20, 2024
Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
Xuanhong Jin, Yang Pan, Cheng Cheng, et al.
Bioactive Materials
|
June 29, 2022
Macrophage membrane-biomimetic adhesive polycaprolactone nanocamptothecin for improving cancer-targeting efficiency and impairing metastasis
Kangkang Ying, Yifeng Zhu, Jianqin Wan, et al.
Plos One
|
June 14, 2013
AIB1 cooperates with ERα to promote epithelial mesenchymal transition in breast cancer through SNAI1 activation
Miao Wang, Feng Zhao, Shujing Li, et al.
Cellular and Molecular Life Sciences : CMLS
|
December 10, 2022
B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis
Xiaoling Zhang, Hao Liu, Haidong Wang, et al.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
|
July 20, 2016
[Establishment of "in-hospital critical illness management system" in general hospital: establishment of "general critical medicine" mode]
Tao Zhu, Daoyang Zhou, Konghan Pan, et al.
Theranostics
|
June 20, 2020
An ultralow dose of the NADPH oxidase inhibitor diphenyleneiodonium (DPI) is an economical and effective therapeutic agent for the treatment of colitis-associated colorectal cancer
Yue Kuai, Hao Liu, Dongyu Liu, et al.
Frontiers in Pharmacology
|
March 21, 2022
Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
Li Chen, Hao Sun, Ruihu Zhao, et al.
Cancer Letters
|
June 7, 2016
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3
Jiawei Shou, Liangkun You, Junlin Yao, et al.
Journal of Cancer
|
August 21, 2018
Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China
Chongya Zhai, Yulan Cai, Fang Lou, et al.
Page
of 27